Celltrion’s Herzuma (trastuzumab, biosimilar) Receives ANVISA’s Approval for Breast and

Shots: The Brazilian Health Regulatory Agency, ANVISA (Agencia Nacional de Vigilancia Sanitaria) has approved Herzuma (trastuzumab) in 150mg & 440mg for early-stage breast cancer, metastatic breast cancer and metastatic gastric cancer on May 20, 2019 Celltrion is also expecting ANVISA’s approval for Truxima, a biosimilar of Rituximab which helps in securing a leading market position […]Read More